Michael Schumacher is still surviving as he continues to battle complications from the near-fatal head injury he sustained while skiing in 2013. It was reported that the F1 legend is set to undergo another round of stem cell procedure that will help regenerate his nervous system.

Facts about the reported new operation on Schumi

With this surgery, his family and doctors are hoping that he will be able to recover functions in parts of his body. This is because it is aimed at his sensory system that was affected by his injuries.

The Daily Mail reported that currently, Michael Schumacher is being treated and cared for by French cardiologist Dr. Philippe Menasche, a medical expert specializing in stem cell research. It was revealed that a series of surgeries are needed for this treatment, so this is just one of the racing champs operations for his recovery.

In an article that appeared in an Italian publication Le Dauphine, it was reported that Dr. Menasche will do seminal heart surgery on Schumi in his next surgery schedule. It was added that this will take place soon, but the exact date was not revealed.

It is also believed that this will be the second time that the said doctor is operating on Michael Schumacher. The first procedure was said to have been done in September 2019, and Schumi was in the hospital for about three days. At any rate, in this operation, his damaged cells will be replaced with healthy ones that will be taken from his bone marrow.

An experimental stem-cell surgery?

Michael Schumacher has not recovered from his accident that happened more than six years ago. He is currently being treated in his own home in Switzerland, but his exact condition is still a mystery since his family continues to keep everything related to his health a secret.

Dr. Nicola Acciari, a leading neurosurgeon, previously claimed that Michael Schumacher has osteoporosis and suffering from muscle atrophy since he is unable to move for years. The goal is to regenerate Michaels nervous system, The Sun quoted him as saying in connection to the stem cell therapy.

However, Jean-Michel Dcugis, a French journalist, shared to British daily national newspaper, The Times, that the procedure is experimental at this point since Dr. Menasche is actually a cardiologist.

"Our sources say that Michael Schumacher is receiving stem cell perfusions that produce a systemic anti-inflammatory effect, The Sun quoted Dcugis as saying. "It's quite mysterious as Menasch works only on the heart. He is carrying out experiments with secretome that is made by a laboratory from new stem cells and injected into veins, until now only on animals.

View post:
Michael Schumacher is reportedly getting another stem-cell surgery; Journalist alleged it will be an experimental procedure - EconoTimes

Bone Marrow Stem Cells Comments Off on Michael Schumacher is reportedly getting another stem-cell surgery; Journalist alleged it will be an experimental procedure – EconoTimes | June 29th, 2020

Boca Raton, FL, June 29 Human leukocyte antigens (HLA) diverse genetic markers on our cells that help match patients and donors for bone marrow transplant are the focus of a new study led by the Gift of Life Marrow Registry.

The study, in collaboration with researchers at Rutgers Cancer Institute of New Jersey and the genetic crowd science portal Root, aims to help answer a key question: why do some people get COVID19 or particular symptoms, while others avoid them? More than 350,000 donors in Gift of Life's registry have been invited to participate, helping researchers answer this important question.

"Every volunteer donor is already HLA-typed, presenting a tremendous opportunity to drive broader science through the prism of these immune-related genes," said Gift of Life's Founder and CEO Jay Feinberg. "We're excited to help the world understand how our immune systems may shape the pandemic."

"We hope to learn whether immune-vital tissue match genes such as HLA help explain why some of us avoid COVID-19, while others get severe symptoms or need particular treatments," said the study's principal investigator Jeffrey Rosenfeld, PhD, Assistant Professor of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School. "Adding such key data to the fight against COVID-19, we can help solve the mystery of why it affects different people so differently."

Subscribe

Root's founder, geneticist Nathaniel Pearson, PhD, noted that "because transplant registries read HLA genes better than consumer DNA tests do, a study like this can best reveal how these diverse, immune-vital genes may shape COVID-19. Gift of Life members, who have long saved lives via transplants, now show us how everyday people can help the world beat a pandemic too."

Participants can also opt into short monthly surveys for the coming year, even if they have never had COVID-19. The researchers will study their de-identified data, to better understand how tissue match genes and other factors may figure in COVID-19 risks and outcomes.

Subscribe

The new study furthers Gift of Life's efforts to help people and communities in need during the pandemic. The organization has increased capacity at the Dr. Miriam and Sheldon G. Adelson Gift of LifeBe The Match Collection Center to become a non-hospital based go-to for stem cell donations and contributed 10,000 specialized swabs to Baptist Health South Florida via Boca Raton Regional Hospital to be used for COVID-19 testing.

About Gift of Life Marrow RegistryThe Gift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life or to make a tax-deductible donation, visit http://www.giftoflife.org.

About Rutgers Cancer Institute of New JerseyAs New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex robotic surgery. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy many of which are not widely available patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit http://www.cinj.org/giving.

About Root

Root (rootdeep.com) works to grow, diversify, and engage the ranks of blood and marrow volunteers earth's biggest group of living, contactable DNA data owners to save patients in need, honor their good will with good insights, and empower them to spark broader health science discoveries with researchers.

See the article here:
Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study - Patch.com

Bone Marrow Stem Cells Comments Off on Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study – Patch.com | June 29th, 2020

A six-year-old who won the nations hearts in his battle with leukaemia has been given a heroes welcome after flying home following months of life-saving cancer treatment in Singapore.

Brave Oscar Saxelby-Lee from St Johns, Worcester, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.

Doctors gave him months to find a stem cell match to save his life which led to parents Olivia Saxelby, 25, and Jamie Lee, 28, launching a UK-wide appeal for donors.

Last March a record-breaking 4,855 volunteers queued in the freezing rain after Oscars primary school in opened as a testing centre.

In total more than 10,000 people were tested across the UK until a match was finally found.

Read more: Mum-to-be plagued by headaches diagnosed with incurable brain tumour

But just months later, the family faced further anguish after discovering Oscars cancer had returned.

After a crowdfunding campaign raised 600,000, Oscar was flown to Singapore for pioneering treatment not available on the NHS.

Oscar became only the second child in the world to undergo CAR-T therapy before having a second bone marrow transplant using stem cells from dad Jamie.

Oscar Saxelby-Lee, with his mum and dad during his time having treatment in Singapore. (SWNS)

Just three months after the successful operation, Oscar and his parents were given the all clear to return to the UK and hours after touching down he was driven see his classmates, who cheered as he drove past the school gates.

In heartwarming pictures Oscar grins from ear to ear as his proud dad sits next to him and his mum breaks down in tears of joy.

Pupils gave Oscar a huge bunch of colourful balloons which the youngster struggled to fit inside the car.

Read more:Woman diagnosed with cancer 48 hours before giving birth

Jen Kelly, from the Grace Kelly Trust which helped raise 173,000 to fund his life-saving treatment, said: The Grave Kelly Trust is delighted to see Oscar returning home to the UK with his mum and dad.

Out smiles have been growing ever wider as we watched Oscars miraculous journey.

We are so proud to have been able to play a key part in Oscars bid for life-saving treatment in Singapore and it is wonderful to see Oscar doing so well following his ground-breaking treatment.

This news is amazing, not just for Oscar, but potentially for other children in a similar position in the future.

Oscar still has a way to go and will need to be shielded for a good while longer once he gets home, but he remains cancer free and smiling.

Read more:Parents spot cancer in babys eye after photo taken

Oscar leaves Hospital in Singapore. (SWNS)

Story continues

Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed Ozzybot.

His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: There have been plenty of ups and downs to get here but this is the absolute icing on the cake that hes come home, cancer free and its worked.

Our future plans now will be to support Oscar and his family and even start some learning at home.

Then we will be working really closely with Olivia, Jamie and Oscar for some transition into school.

That will be the best day when he walks back through the door at Pitmaston Primary.

Oscar made a surprise visit to his classmates on his return from Singapore. (SWNS)

When he left hospital for the final time in Singapore Ozzy, as he is affectionately nicknamed, was given a guard of honour by medical staff.

A video posted on the Hand in Hand for Oscar Facebook page, shows the youngster beaming as he is driven away and shouts: Bye hospital, thank you!

Read more: Six-year-old runs marathon for the NHS dressed as his favourite super-heroes

His thrilled mum Olivia wrote: Cant quite believe it, crying bucket loads! The day weve dreamt of has now become a reality!

Were actually bringing him home!!!

You are our HERO Ozzy Bear, you truly truly are the most amazing miracle.

Enjoy every last minute of this journey darling, because YOU have owned [sic] it!

Additional reporting SWNS.

See the article here:
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore - Yahoo Lifestyle UK

Bone Marrow Stem Cells Comments Off on Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore – Yahoo Lifestyle UK | June 29th, 2020

VANCOUVER, Washington, June 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn” or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Company and the Coordinating Commission of the National Institutes of Health and High Specialty Hospitals of Mexico (NIH) have entered into a Memorandum of Understanding (MOU) to conduct a COVID-19 clinical trial with leronlimab for severe and critically ill patients, with the potential to collaborate on additional COVID-19 trials. The NIH of Mexico is an organization that coordinates the main institutions of medical care and public research in the country.

The MOU provides CytoDyn will supply leronlimab at its expense to the NIH and both parties are proceeding forward expeditiously to complete the mutually agreed protocol for this clinical trial.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented: We are very pleased with the confidence demonstrated by the NIH of Mexico in our drug, leronlimab, and we are both very motivated to initiate this trial quickly to help mitigate the devastation of the COVID-19 pandemic on the citizens of Mexico. The anecdotal data received by CytoDyn (from over 70 COVID-19 critical patients who were treated under EIND in the U.S.) has impressed the NIH of Mexico and we believe with a small Phase 3 trial of only 25 patients, leronlimab could receive approval in Mexico very quickly. This Phase 3 trial is similar to our Phase 3 trial protocol in the U.S., with the exception of the number of patients.”

About Coronavirus Disease 2019 CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy The FDA has granted a Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients with the FDA on April 27, 2020, and submitted additional FDA requested clinical datasets on May 11, 2020. After the FDA deems a BLA submission complete, it sets a PDUFA goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA. The Company filed a request for Priority Review designation for its BLA to shorten the FDA’s review time from 10 to 6 months, an FDA goal for BLA applications given Priority Review designation.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug” designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes,” hopes,” intends,” estimates,” expects,” projects,” plans,” anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTS Investors: Cristina De Leon Office: 360.980.8524, ext. 106 Mobile: 503.214.0872 cdeleon@cytodyn.com

Go here to read the rest:
CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients -...

Bone Marrow Stem Cells Comments Off on CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients -… | June 29th, 2020

The COVID-19 pandemic has been a shock for most people, but for Clay Drake, much of it was familiar: the need to stay in, the stocking up on hand sanitizer, the concern that a simple trip to church could turn deadly.

Drake, of Windsor, has multiple myeloma, a blood cell cancer, and underwent two stem cell transplants that knocked out his immune system for months. A bout with the seasonal flu lasted more than a month, and for a while he was getting colds that took him weeks to shake, he said.

That was my COVID, he said. I spent probably about a year doing what everybody started doing in March.

While many though not all healthy people who get COVID-19 can recover at home, those who have chronic conditions are six times as likely to be hospitalized and 12 times as likely to die, according to a report from the Centers for Disease Control and Prevention.

Drake still gets chemotherapy and immunotherapy treatments to keep the cancer in remission. Because of the heightened risk from infections, he tries to minimize trips to crowded places but has started seeing small groups of friends again and occasionally eating out. Most people around Windsor seem to be wearing masks and following other recommendations, which makes it safer, he said.

For the most part, I feel comfortable going out in public, he said.

People who have chronic conditions need to be vigilant about social distancing, wearing a mask and washing their hands, according to the CDC, and should talk to their doctors about additional precautions.

While those who know they face a higher risk of dying can take some steps to protect themselves, the rest of the community also needs to help keep the virus from breaking out, said Dr. Peter Buttrick, a cardiologist and member of the board for the Denver branch of the American Heart Association. Most people who get the virus can spread it before developing symptoms, meaning they could inadvertently give it to someone whos at a higher risk especially if they arent wearing masks, he said.

The likelihood youll be in contact with someone who is infected and asymptomatic is higher when theres ongoing community spread, he said.

Colorados new cases are down from a peak in April, but theyve started to tick back up and Gov. Jared Polis has urged the public to continue avoiding large events and wearing masks.

The Centers for Disease Control and Prevention released an updated list Thursday of the clearest risk factors for getting severely sick or dying from COVID-19:

The CDC also listed other conditions as possible risk factors, though the evidence is mixed or from small studies:

A large study in the United Kingdom found that the risk of dying increased sharply with age, but younger people were also at a higher risk if they had certain conditions, said Dr. Jonathan Samet, dean of the Colorado School of Public Health. Diabetes and chronic lung conditions such as emphysema roughly doubled the risk of dying compared to a healthy person of the same age, and heart disease increased the risk by about 25%. Obesity also raised a persons risk of complications, he said.

About 7% of adults in Colorado have diabetes and 23% have obesity, which are some of the lowest rates in the country, according to Americas Health Rankings. Still, that means thousands of people are at an elevated risk, and not all of them may have the ability to stay at home. Ideally, those who are at a high risk would continue social distancing at a high level, Samet said.

Its certainly a time for caution, if peoples jobs and lives allow it, he said.

Not everyone with diabetes is at an equal risk, said Dr. Robert Gabbay, chief scientific and medical officer for the American Diabetes Association. People who have poorly controlled blood sugar and have other chronic conditions generally are at a higher risk from infections, including COVID-19. That makes it important to keep in touch with your doctor and to manage your diabetes well, he said.

If you have diabetes, you have high blood sugars, youre obese and you have maybe cardiovascular disease, youre at high risk and you need to be really careful, he said, adding that age also is a factor to consider.

Its not entirely clear why certain conditions are linked to a higher risk of complications. One possibility is that when hearts are stressed by high blood pressure or coronary artery disease, their cells produce more of certain receptors that the virus binds to though more research is needed to understand if thats the issue, Buttrick said. He urged people not to put off seeking medical advice if they have symptoms that could suggest heart trouble, such as chest pain, shortness of breath, heart palpitations or fainting not only because of the virus risk, but also because the problem itself may need immediate treatment.

Heart disease doesnt go on vacation during the pandemic, he said.

Buttrick and Samet dont advise people with chronic illnesses to stay at home at all times, but say they should consider ways to avoid crowds, like visiting the grocery store during hours set aside for high-risk customers. Ultimately, each patient and doctor need to discuss individual risks, though.

Im telling all of my patients, and I think everybody is, that if youre of a certain age, you need to be really careful, Buttrick said.

People with diabetes and other conditions have to consider their individual level of risk, as well as how risky any particular activity is, Gabbay said. If you have well-controlled blood sugar and no other chronic conditions, you might feel more comfortable going to a lower-risk social event, while someone whose health is more precarious might avoid any exposure that isnt absolutely necessary.

Thats whats made this so difficult there are no hard and fast rules, he said.

Hyoung Chang, The Denver Post

Drake, who volunteers with the American Cancer Society, said he sometimes gets calls from people trying to figure out what they should do, and he steers them toward the ACS guidelines. Some of them are particularly worried about how to move forward with cancer treatment during a pandemic, he said.

I feel like theres a lot of people, particularly the more susceptible and elderly, who are scared, he said.

Subscribe to bi-weekly newsletter to get health news sent straight to your inbox.

Visit link:
COVID threat isnt over, especially for Coloradans with chronic conditions - The Denver Post

Bone Marrow Stem Cells Comments Off on COVID threat isnt over, especially for Coloradans with chronic conditions – The Denver Post | June 29th, 2020

On Aug. 4, Hutchinson Regional Medical Center will open the Hutchinson Hematology and Oncology clinic. Dr. Sawsan Amireh will join the Hutch Regional team that day and see her first patients at her clinic which will be located in Suite 4 of Doctors Park at 2100 N. Waldron St., a building located to the southwest of the main hospital campus on the east side of Waldron Street.

Hematology and Oncology are two branches of medicine that continue to be a concern of members of our community and throughout the State of Kansas.

Oncology is the branch of medical science dealing with tumors, including the diagnosis and treatment of cancer. More than 1.8 million Americans, including 16,000 Kansans, are diagnosed with cancer each year. For more than 600,000 of our nations population each year, cancer is a terminal disease. The good news is that 17 million Americans are living out their lives as cancer survivors.

Cancer is best defined as the uncontrolled growth and spread of abnormal cells and the cause is often attributed to everything from heredity to an unhealthy lifestyle including tobacco use and excess weight. Treatments are medical, surgical, Chemotherapy and Radiation.

Hematology is the branch of medicine dealing with the cause, treatment and prevention of disease related to the blood. Specific issues dealt with include treatment of bleeding disorders, Lymphoma and Leukemia and blood transfusions, along with bone marrow and stem cell transplants.

Dr. Amireh, who has received training on the latest treatment protocols, arrives at Hutch Regional with impeccable credentials and is Board Certified in Internal Medicine. She received her doctorate degree in 2011 from the University of Jordan School of Medicine in Amman, Jordan. Since 2017, Dr. Amireh has participated in a Hematology and Oncology Fellowship and also served as chief fellow with the State University of New York Downstate Health Science Center in Brooklyn, New York. Also, Dr. Amireh served as Associate Chief Medical Resident and Internal Medical Resident at Saint Michaels Medical Center in New Jersey.

In 2010, Dr. Amireh completed special training at Vanderbilt University Medical Center in Nashville, Tennessee on Hepatology and Pediatric Endocrinology. She has won numerous awards and honors including the Clinical Documentation Excellence Award from St. Michaels Medical Center, the Academic Excellence Award from the University of Jordan School of Medicine, and the English Talented Writing Award from the University of Jordan.

Dr. Amireh is a member of the American Society of Clinical Oncology, American Society of Hematology, American College of Physicians, and the Jordan Medical Association.

Dr. Amireh said Oncology has entered a new era with the onset of COVID-19. "Cancer patients are now more vulnerable and will need to be more diligent to avoid infection which proves that life is more fragile than it once was," Dr. Amireh said. "I am looking forward to starting a hospital-based practice. We have a young family and southcentral Kansas is a good place to raise a two-year old. New York is too busy and not really family friendly."

"I want my practice to be inclusive and will welcome everyone who needs treatment and care," Dr. Amireh continued.

Appointments with Dr. Amireh will be accepted starting in Mid-July. Additional information including her clinics contact information will be published at that time.

With the opening of Hutchinson Hematology and Oncology, south central and western Kansas will have a new choice for quality cancer care. Dr. Amireh will provide a caring, personal approach to cancer care and her clinic will work in tandem with the Chalmers Cancer Center and the other Hutchinson Regional Healthcare System entities as well as other physician specialties in Hutchinson and surrounding communities to provide an integrated approach to care in Hutchinson.

Dr. Amireh will join her spouse, Dr. Mohammed "Mo" Al-Halawani at Hutch Regional. In July 2019, Dr. Al-Halawani joined Dr. Tariq Musa in opening Hutchinson Pulmonology Associates at Hutchinson Regional Medical Center. Dr. Al-Halawani and Dr. Musa hit the ground running and are serving patients in Hutchinson as well as an outreach clinic in McPherson, with plans to support pulmonary needs locally and in the surrounding areas.

We are excited that these high caliber healthcare professionals have chosen to move across America to provide their expertise to residents on the plains of Kansas.

Ken Johnson is the President and CEO of Hutchinson Regional Medical Center.

Continue reading here:
HRMC to open hematology and oncology clinic - The Ottawa Herald

Bone Marrow Stem Cells Comments Off on HRMC to open hematology and oncology clinic – The Ottawa Herald | June 29th, 2020

By: Lifestyle Desk | New Delhi | Updated: June 27, 2020 12:09:31 pm Heres everything to know about the blood disorder. (Source: Getty Images/Thinkstock)

Sickle cell disease (SCD) is an inherited group of blood disorder which is genetic in nature. It is usually transferred from parents to the child during birth i.e. both the parents can be carries of SCD. Healthy RBCs are round in shape, which moves through small blood vessels and carries oxygen to all parts of the body. In someone who has SCD, the RBC becomes sticky and hard and start to look like C- shaped similar to that of a farm tool sickle. The sickle cells die early, which causes a constant shortage of RBC, which leads to low oxygen carriers in the body, mentioned Dr Rahul Bhargava, director and head, haematology and bone marrow transplant, Fortis Memorial Research Institute, Gurugram. Also, when sickle cells travels they tend to get stuck in small blood vessels and restrict the blood flow. This can cause pain in the joints, chest and other serious problems such as stroke, acute chest syndrome and infections.

Anaemia

SCD can lead to shortage of RBC which makes the patient anaemic. It can lead to less oxygen supply in the body causing fatigue.

Episodes of pain. SCD patients suffer from episodes of periodic pain. Sickle-shaped blood cells can block the flow of blood which in tiny vessels of abdomen, chest and joints, thus leading to pain.

Feet and hands swelling

Sickle-shaped RBC can block then flow of blood which can cause swelling in the hands and feet.

Frequent infections

Sickle cells can damage the spleen and make the person vulnerable to diseases and infections. Vaccination is usually prescribed in childhood to keep infections at bay.

Delayed growth or puberty

RBC is the carrier of oxygen and other nutrients. With low RBC, there is no enough oxygen in the body which can slow the growth in infants and children which leads to delayed puberty in children.

Vision problems

Vision is affected when the flow of blood is affected.

SCD can lead to a lot of complication, including Stroke, acute chest syndrome, pulmonary hypertension, organ damage, blindness, leg ulcers and more such complications.

SCD can be diagnosed with a simple blood test. Parents are advised to get the screening done before conceiving as it is transmitted from parents. For newborns, the test is done in the hospitals as a routine screening. There is no single treatment for SCD patients and it varies from patient to patient on the basis the symptoms. Before starting any medication, consult a haematologist who specialises in blood disorders.

The only cure for SCD is getting a bone marrow transplant (BMT), which is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Stem cells are easily taken from the donor and planted in the recipient. After the BMT procedure, the patient can lead a healthy and normal life.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read more:
Sickle Cell Disease: All you need to know - The Indian Express

Bone Marrow Stem Cells Comments Off on Sickle Cell Disease: All you need to know – The Indian Express | June 29th, 2020

A six-year-old who won the nations hearts in his battle with leukaemia has been given a heroes welcome after flying home following months of life-saving cancer treatment in Singapore.

Brave Oscar Saxelby-Lee from St Johns, Worcester, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.

Doctors gave him months to find a stem cell match to save his life which led to parents Olivia Saxelby, 25, and Jamie Lee, 28, launching a UK-wide appeal for donors.

Last March a record-breaking 4,855 volunteers queued in the freezing rain after Oscars primary school in opened as a testing centre.

In total more than 10,000 people were tested across the UK until a match was finally found.

Read more: Mum-to-be plagued by headaches diagnosed with incurable brain tumour

But just months later, the family faced further anguish after discovering Oscars cancer had returned.

After a crowdfunding campaign raised 600,000, Oscar was flown to Singapore for pioneering treatment not available on the NHS.

Oscar became only the second child in the world to undergo CAR-T therapy before having a second bone marrow transplant using stem cells from dad Jamie.

Oscar Saxelby-Lee, with his mum and dad during his time having treatment in Singapore. (SWNS)

Just three months after the successful operation, Oscar and his parents were given the all clear to return to the UK and hours after touching down he was driven see his classmates, who cheered as he drove past the school gates.

In heartwarming pictures Oscar grins from ear to ear as his proud dad sits next to him and his mum breaks down in tears of joy.

Pupils gave Oscar a huge bunch of colourful balloons which the youngster struggled to fit inside the car.

Read more:Woman diagnosed with cancer 48 hours before giving birth

Jen Kelly, from the Grace Kelly Trust which helped raise 173,000 to fund his life-saving treatment, said: The Grave Kelly Trust is delighted to see Oscar returning home to the UK with his mum and dad.

Out smiles have been growing ever wider as we watched Oscars miraculous journey.

We are so proud to have been able to play a key part in Oscars bid for life-saving treatment in Singapore and it is wonderful to see Oscar doing so well following his ground-breaking treatment.

This news is amazing, not just for Oscar, but potentially for other children in a similar position in the future.

Oscar still has a way to go and will need to be shielded for a good while longer once he gets home, but he remains cancer free and smiling.

Read more:Parents spot cancer in babys eye after photo taken

Oscar leaves Hospital in Singapore. (SWNS)

Story continues

Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed Ozzybot.

His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: There have been plenty of ups and downs to get here but this is the absolute icing on the cake that hes come home, cancer free and its worked.

Our future plans now will be to support Oscar and his family and even start some learning at home.

Then we will be working really closely with Olivia, Jamie and Oscar for some transition into school.

That will be the best day when he walks back through the door at Pitmaston Primary.

Oscar made a surprise visit to his classmates on his return from Singapore. (SWNS)

When he left hospital for the final time in Singapore Ozzy, as he is affectionately nicknamed, was given a guard of honour by medical staff.

A video posted on the Hand in Hand for Oscar Facebook page, shows the youngster beaming as he is driven away and shouts: Bye hospital, thank you!

Read more: Six-year-old runs marathon for the NHS dressed as his favourite super-heroes

His thrilled mum Olivia wrote: Cant quite believe it, crying bucket loads! The day weve dreamt of has now become a reality!

Were actually bringing him home!!!

You are our HERO Ozzy Bear, you truly truly are the most amazing miracle.

Enjoy every last minute of this journey darling, because YOU have owned [sic] it!

Additional reporting SWNS.

View original post here:
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore - Yahoo Singapore News

Bone Marrow Stem Cells Comments Off on Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore – Yahoo Singapore News | June 29th, 2020

There are so many skincare brands on the market today, their number may flood your social media feed that it may be difficult to choose the right one for you this summertime. Sensitive skin, aging, tired skin, fair, dark, or a combination, its particularly rare for a single product or brand that can nourish and protect you during this season. However, by using a variety of brands that suit you, you may achieve that glowing healthy skin youve always wanted.

Here is a list of 8 products and options that can help you obtain the perfect skin this summer:

This brand is inspired and designed by leading cosmeceutical scientists for skincare, anti-aging, removal of blemish, and other skin issues. Their products are clinically tested, which makes SkinPro represent the industrys advanced skincare technology. Its perfect for enjoying the sun during the day and experience the rejuvenating effects with strengthened efficacy while being sensitive to the skin. The formulations are made by proprietary technology to give you a special combination of active ingredients that will remedy skin problems and provide lasting results.

Pair your tan with skincare that keeps your skins aging process to a minimum while enjoying the sun. You can use the Nimni Day Cream to protect and smoothen your skin with special collagen boosting complex infused with environmental shields. Summer-soft touchable skin is truly achievable while preventing possible daytime sun damage. When the sun sets and before going to bed to close another day, use the Nimni Night Cream and take some time to yourself.

Caudalie is a French skincare brand, based on all-natural grape extracts from the Bordeaux, Champagne, and Burgundy regions. Red wine drinkers already know this to be true: grapes are high in antioxidants and resveratrol compounds and polyphenols which give the whole line its unique and successful philosophy of anti-aging.

The whole line of SK-II revolves on a special ingredient called Pitera. History has it that workers who were subjected to a fermentation substance at a Japanese factory have remarkably ageless and spotless palms. In a slew of anti-aging creams, serums, masks, and most famously a skin-brightening facial treatment essence the secret sauce was packaged up and shipped.

It is one of those skincare brands that you can apply by yourself or as an aftercare treatment based on your preferences and goals. CosmetiCare has everything you need to fix anti-aging, acne, or pigmentation so you can get a sun-radiant, healthy, vibrant complexion. Using their Amplify-Hyaluronic Acid Enhancing Serum to lighten your dry skin with moisture when strengthening the skins lipid barrier. It is especially good for your summer skin, which requires the extra boost from day to day activities to keep your skin moisturized.

Think of skincare product creativity! If youre hunting for skincare brands with coveted distinctions to be the best-selling brands, then youll meet Factor Five Skin here. With this best-selling serum, take your regimen to a whole new dimension that dares to deviate from conventional anti-aging products. Their Regenerative Serum works on wrinkles, sun spots, uneven texture, and more. Combining human stem cell growth factors with copper peptides will make your skin look renewed and restored in as little as 4 weeks!

Your time in the sun is not supposed to reveal the years of skin life. This youth-infusing bundle of skin-loving ingredients is nicely packaged in the Mature Skin Anti-Aging Kit to help you reverse or prevent premature aging. Turn back the time or stand still with this scientifically crafted and evidence-based ingredient combination. Prepare to erase the fine lines, wrinkles, and discolorations of the skin, and shrink large pores with this impressive collection of anti-aging skincare:

This summer, when you apply the Mature Skin Anti-Aging Kit to your regimen, your sun-kissed lips, eyes, and dcolletage region will be completely plumped up and beautifully radiant. Cap off the week with the Hydroxy Overnight Mask, an exfoliating and hydrating leave-on-night mask composed of salicylic acids.

If you tend to have skin that is prone to acne, oily, sun-damaged, or sensitive, then you will want to use this product a few times a week. The Aloe Veras soothing compounds help soothe drained, old skin cells when youre asleep! You can use it as a mask or even best as a spot-treatment for rare breakouts, and youd wake to clean and healthy skin.

Who wouldnt love skincare brands that make an utter joy in washing your face? Only the word Kale Cleanser makes you want to make every morning and evening a spa day in your house! Its a concentrated combination of superfoods and antioxidants that hydrate your skin while reducing oxidative damage to the blue light. Its so sweet, you should probably use it twice a day and wash the dirt and extra grime of the day away. Follow it up next with the Moisturizer Adaptogens Superfruits.

This yummy moisturizer feeds some of the most powerful anti-aging ingredients to amplify the natural development of collagen in your skin while helping to prevent free-radical damage. Then what better way to soothe your exposed skin during the summer than with the Adaptogens Superfruits Mask. The sun may be bright, but if it is not revitalized, it can quickly dull your skin. Its creamy, smooth, and not only smells great, but after just one try, it leaves your skin smooth and rejuvenated. Piper Berry is one of the skincare brands that we love for quick fixing and refreshing the skin anytime, anywhere.

With these products, youll be summer-ready to enjoy activities that you can only do when the suns out while protecting and nourishing your skin. If you have sensitive skin make sure to apply only a small amount and gradually increase when you dont show any signs of negative reaction. Investing in the protection and rejuvenation of your skin will surely hold off father time from getting his hands on your glowing face.

The rest is here:
Skincare Brands To Try Out This Summer - GirlTalkHQ

Skin Stem Cells Comments Off on Skincare Brands To Try Out This Summer – GirlTalkHQ | June 28th, 2020

Just like your skin, your hair also needs pampering to look good. For lustrous and long tresses, you need to provide your scalp and hair follicles with the essential nutrients including vitamins, minerals, and proteins. Though there are various supplements available in the market that can stimulate your hair growth, if you wish to go natural, there is a plethora of food items that can give you the same benefit. Read further to know about foods that can promote hair growth. Also Read - Want to Promote Hair Growth And Relieve Insomnia? Opt For Spikenard Essential Oil

Being rich in procyanidin B-2, apples can stimulate epithelial cells and promote hair growth. Also, the antioxidants present in this fruit can fight against the free radicals and reduce hair damage. Even if you wish to improve your hair thickness, you can have apples as they are packed with protein. Also Read - Potential stem cell therapy may help promote hair growth

Strawberries contain vitamin C and other strong antioxidants, that can improve the health of your hair. If anecdotal evidences are to be believed, silica present in strawberries can stop hair loss and prevent the onset of baldness. Eating strawberries every day can treat dandruff and also make your hair appear shiny. Also Read - Top 5 essential oils for hair growth and how to use them

Bananas can help in hair growth by preventing dandruff and improving the quality of your scalp. Its rich nutritional content can also unclog the scalp pores. If you want your hair to impart shine, have a banana every day. It can also prevent breakage and split-ends.

See more here:
Best Hair Growth Tips: 5 Food Items to Include in Your Daily Diet For Long And Strong Tresses - India.com

Skin Stem Cells Comments Off on Best Hair Growth Tips: 5 Food Items to Include in Your Daily Diet For Long And Strong Tresses – India.com | June 28th, 2020

Unfortunate news for those hoping the coronavirus pandemic was fading away: models suggest that an apocalyptic resurgence could be coming in the near future.

Multiple U.S. states, including Florida, Texas, and California, are currently experiencing record daily numbers of new COVID-19 cases, CNN reports. And they all still seem to be on the upswing.

Dr. Peter Hotez, dean of Baylor College of Medicines National School of Tropical Medicine, told CNN that Houston is on track to be the most coronavirus-ravaged city in the U.S. but that other Texas cities arent far behind.

The big metro areas seem to be rising very quickly and some of the models are on the verge of being apocalyptic, Hotez told CNN.

The three states hitting record numbers right now are also the most populous in the country. Combined, their new surges put more than 27 percent of the U.S. population at risk, CNN reports.

Hotez, whos also working on an experimental COVID-19 vaccine, warns that Houston in particular may quadruple its coronavirus case load over the next two weeks, which would put the same devastating strain on its healthcare system that places like New York City experienced earlier in the year.

That is really worrisome and as those numbers rise, were seeing commensurate increases in the number of hospitalizations and ICU admissions, Hotex told CNN. You get to the point where you overwhelm ICUs and thats when the mortality goes up.

Visit link:
Professor: Looming COVID Surge on "Verge of Being Apocalyptic" - Futurism

Skin Stem Cells Comments Off on Professor: Looming COVID Surge on "Verge of Being Apocalyptic" – Futurism | June 28th, 2020

This report will definitely help you make well informed decisions related to the stem cell market. The stem cell therapy market includes large number of players that are involved in development of stem cell therapies of the treatment of various diseases. Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are the key players involved in the development of stem cell therapies across the globe.

The global stem cells market is expected to grow at an incredible CAGR of 25.5% from 2018to 2024and reach a market value of US$ 586 billion by 2025. The emergence of Induced Pluripotent Stem (iPS) cells as an alternative to ESCs (embryonic stem cells), growth of developing markets, and evolution of new stem cell therapies represent promising growth opportunities for leading players in this sector.

You Can Browse Full Report @: https://www.marketresearchengine.com/reportdetails/global-stem-cells-market-analysis-report

Due to the increased funding from Government and Private sector and rising global awareness about stem cell therapies and research are the main factors which are driving this market. A surge in therapeutic research activities funded by governments across the world has immensely propelled the global stem cells market. However, the high cost of stem cell treatment and stringent government regulations against the harvesting of stem cells are expected to restrain the growth of the global stem cells market.

The stem cell therapy market includes large number of players that are involved in development of stem cell therapies of the treatment of various diseases. Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are the key players involved in the development of stem cell therapies across the globe.

This market research report categorizes the stem cell therapy market into the following segments and sub-segments:

The Global Stem Cell Market this market is segmented on the basis of Mode of Therapy, Therapeutic Applications and Geography.

By Mode of Therapy this market is segmented on the basis of Allogeneic Stem Cell Therapy Market and Autologous Stem Cell Therapy Market. Allogeneic Stem Cell Therapy Market this market is segmented on the basis of CVS Diseases, CNS Diseases, GIT diseases, Eye Diseases, Musculoskeletal Disorders, Metabolic Diseases, Immune System Diseases, Wounds and Injuries and Others. Autologous Stem Cell Therapy Market this market is segmented on the basis of GIT Diseases, Musculoskeletal Disorders, CVS Diseases, CNS Diseases, Wounds and Injuries and Others. By Therapeutic Applications this market is segmented on the basis of Musculoskeletal Disorders, Metabolic Diseases, Immune System Diseases, GIT Diseases, Eye Diseases, CVS Diseases, CNS Diseases, Wounds and Injuries and Others.

By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

Request Sample Report @: https://www.marketresearchengine.com/reportdetails/global-stem-cells-market-analysis-report

Table of Contents

1 INTRODUCTION

2 Research Methodology

2.1 Research Data2.1.1 Secondary Data2.1.1.1 Key Data From Secondary Sources2.1.2 Primary Data2.1.2.1 Key Data From Primary Sources2.1.2.2 Breakdown of Primaries2.2 Market Size Estimation2.2.1 Bottom-Up Approach2.2.2 Top-Down Approach2.3 Market Breakdown and Data Triangulation2.4 Research Assumptions

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Global Stem Cell Therapy Market, By Type

8 Global Stem Cell Therapy Market, By Therapeutic Application

9 Global Stem Cell Therapy Market, By Cell Source

10 Stem Cell Therapy Market, By Region

11 Competitive Landscape

12 Company Profiles

12.1 Introduction

12.1.1 Geographic Benchmarking

12.2 Osiris Therapeutics, Inc.

12.3 Medipost Co., Ltd.

12.4 Anterogen Co., Ltd.

12.5 Pharmicell Co., Ltd.

12.6 Holostem Terapie Avanzate Srl

12.7 JCR Pharmaceuticals Co., Ltd.

12.8 Nuvasive, Inc.

12.9 RTI Surgical, Inc.

12.10 Allosource

Other Related Market Research Reports:

Specialty Enzymes Market Size Worth US$ 5.5 Billion By 2022

Single Use Bioprocessing Market Size is Projected to be Around US$ 5.50 Billion By 2022

Single-cell Analysis Market is Expected to Grow US$ 3 Billion By 2022

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Excerpt from:
Global Stem Cells Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty

IPS Cell Therapy Comments Off on Global Stem Cells Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE – Cole of Duty | June 26th, 2020

A six-year-old who won the nations hearts in his battle with leukaemia has been given a heroes welcome after flying home following months of life-saving cancer treatment in Singapore.

Brave Oscar Saxelby-Lee from St Johns, Worcester, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.

Doctors gave him months to find a stem cell match to save his life which led to parents Olivia Saxelby, 25, and Jamie Lee, 28, launching a UK-wide appeal for donors.

Last March a record-breaking 4,855 volunteers queued in the freezing rain after Oscars primary school in opened as a testing centre.

In total more than 10,000 people were tested across the UK until a match was finally found.

Read more: Mum-to-be plagued by headaches diagnosed with incurable brain tumour

But just months later, the family faced further anguish after discovering Oscars cancer had returned.

After a crowdfunding campaign raised 600,000, Oscar was flown to Singapore for pioneering treatment not available on the NHS.

Oscar became only the second child in the world to undergo CAR-T therapy before having a second bone marrow transplant using stem cells from dad Jamie.

Oscar Saxelby-Lee, with his mum and dad during his time having treatment in Singapore. (SWNS)

Just three months after the successful operation, Oscar and his parents were given the all clear to return to the UK and hours after touching down he was driven see his classmates, who cheered as he drove past the school gates.

In heartwarming pictures Oscar grins from ear to ear as his proud dad sits next to him and his mum breaks down in tears of joy.

Pupils gave Oscar a huge bunch of colourful balloons which the youngster struggled to fit inside the car.

Read more:Woman diagnosed with cancer 48 hours before giving birth

Jen Kelly, from the Grace Kelly Trust which helped raise 173,000 to fund his life-saving treatment, said: The Grave Kelly Trust is delighted to see Oscar returning home to the UK with his mum and dad.

Out smiles have been growing ever wider as we watched Oscars miraculous journey.

We are so proud to have been able to play a key part in Oscars bid for life-saving treatment in Singapore and it is wonderful to see Oscar doing so well following his ground-breaking treatment.

This news is amazing, not just for Oscar, but potentially for other children in a similar position in the future.

Oscar still has a way to go and will need to be shielded for a good while longer once he gets home, but he remains cancer free and smiling.

Read more:Parents spot cancer in babys eye after photo taken

Oscar leaves Hospital in Singapore. (SWNS)

Story continues

Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed Ozzybot.

His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: There have been plenty of ups and downs to get here but this is the absolute icing on the cake that hes come home, cancer free and its worked.

Our future plans now will be to support Oscar and his family and even start some learning at home.

Then we will be working really closely with Olivia, Jamie and Oscar for some transition into school.

That will be the best day when he walks back through the door at Pitmaston Primary.

Oscar made a surprise visit to his classmates on his return from Singapore. (SWNS)

When he left hospital for the final time in Singapore Ozzy, as he is affectionately nicknamed, was given a guard of honour by medical staff.

A video posted on the Hand in Hand for Oscar Facebook page, shows the youngster beaming as he is driven away and shouts: Bye hospital, thank you!

Read more: Six-year-old runs marathon for the NHS dressed as his favourite super-heroes

His thrilled mum Olivia wrote: Cant quite believe it, crying bucket loads! The day weve dreamt of has now become a reality!

Were actually bringing him home!!!

You are our HERO Ozzy Bear, you truly truly are the most amazing miracle.

Enjoy every last minute of this journey darling, because YOU have owned [sic] it!

Additional reporting SWNS.

Read this article:
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore - Yahoo Canada Sports

Bone Marrow Stem Cells Comments Off on Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore – Yahoo Canada Sports | June 26th, 2020

Dana-Farber Patient Recovering Well After Cancer and the Coronavirus

Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.

None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.

When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.

A Blood Cancer Diagnosis

In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.

Dobay, who lives in Holbrook, MA, was placed under the care ofCorey Cutler, MD, MPH, medical director of theAdult Stem Cell Transplantation Programat Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.

In September 2018, just six months after her diagnosis, Dobay underwent areduced-intensity transplant(sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.

The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.

This article was originally published on June 18, 2020, by Dana-Farber Cancer Institute. It is republished with permission.

View original post here:
Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News

Bone Marrow Stem Cells Comments Off on Recovering from Cancer, a Stem Cell Transplant and Coronavirus – Cancer Health Treatment News | June 26th, 2020

The Cell Therapy Manufacturing Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Cell Therapy Manufacturing market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Cell Therapy Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

The facts and data are represented in the Cell Therapy Manufacturing report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The research report also focuses on global major leading industry players of Cell Therapy Manufacturing market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Cell Therapy ManufacturingMarket Key Companies:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

The predictions mentioned in the Cell Therapy Manufacturing market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Segmentation Overview:

The report provides an in-depth analysis of the Cell Therapy Manufacturing market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

Key Questions Answered in Report:

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://medium.com/@varshashirode0000/global-blockchain-in-genomics-market-trends-analysis-and-forecast-till-2029-3f92b8bdc622

Read the original post:
Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 - 3rd Watch News

Bone Marrow Stem Cells Comments Off on Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 – 3rd Watch News | June 26th, 2020

CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.

About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105[emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

Originally posted here:
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute...

Skin Stem Cells Comments Off on Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute… | June 26th, 2020

Editors note: Exposure to UV-C light poses known threats to human health. While the research discussed in this story examined ways that UV-C might be broadly deployed to stem the spread of COVID-19, it is presented only as information about new research. Readers are strongly cautionednot to experiment on their own with UV-C as an antimicrobial measure.

COVID-19 has upended society and brought chaos to generous swaths of the global economy, as governments have locked down to prevent the spread of the virus. The pandemic has also boosted interest in a variety of technologies that might help in the coronavirus fightincluding the use of ultraviolet light to sterilize scarce personal protective equipment (PPE) such as face masks, for reuse.

In recent papers, two research teams have now proposed approaches to take the use of UV-C much farther. The two groups lay out different schemes for using this high-energy light to scrub the pandemic virus from the air in occupied indoor spaceswhile still keeping the occupants safe from the usual harmful long-term effects of exposure to UV radiation. The teams argue that the approaches they suggest, if widely adopted, could sharply reduce viral transmission in public indoor spaces, and thereby help the world resume something closer to normal economic activity.

The antimicrobial effects of UV-C lightwhich occupies the wavelength band from 200 to 280 nmhave long been known, and 254-nm mercury-vapor germicidal lamps are routinely used to disinfect empty hospital rooms, clean up tainted water, and otherwise cleanse surfaces and areas where bacteria and viruses may lurk. The problem is that the same light that hammers pathogenic airborne bacteria also wreaks havoc on human cells, with long-term impacts such as skin cancer and eye damage.

As a result, much of the recent interest in leveraging UV-C light against the COVID-19 virus, SARS-CoV-2, has centered around possible uses in disinfecting PPE for doctors, nurses and first responders. (One such effort, focusing on a low-cost system that can be used to disinfect scarce N95 face masks for reuse in resource-limited areas, is being pursued by an interdisciplinary team including OSA Fellow and past president Thomas Baer.)

The teams behind the two recent papers favor substantially broadening the use of UV-C against SARS-CoV-2. They suggest that, with the right precautions and setups, the light might be used as a prophylactic in occupied indoor spaces such as workplaces, schools, hospitals and other public areas, silently scrubbing the air of the coronavirus even as the occupants of the buildings go about their daily lives.

One of the studies was led by OSA Fellow Javier Garca de Abajo of the Institute of Photonic SciencesICFO, Spain, and tapped a multinational, interdisciplinary team of researchers in virology, aerosols, immunology and other areas (ACS Nano, doi: 10.1021/acsnano.0c04596). In the study, the researchers looked at how the judicious, strategic installation of UV-C sources might attack the most common routes of indoor viral transmission.

The team began by inventorying the indoor places and systems most likely to spread the virus. These, the researchers argue, include interior ventilation systems in a wide range of settings, which can spread airborne viruses; infrastructure items touched by many persons, such as elevator buttons, stair rails and public-transit handles; and common public facilities with repeated, periodic high use, such as public toilets, storerooms and other areas.

The ICFO-led team argues that antimicrobial UV-C light sources could be placed in a variety of locations associated with viral spread, such as ventilation systems and other areas. The lamps could then be operated without a direct optical pathto humans, or while the roomsare not in use, to help reduce virus propagation without endangering human health. [Image: Sketches by Nacho Gaubert] [Enlarge image]

The team then analyzed how a range of UV-C sources, including LEDs and conventional mercury-vapor lamps, could be safely deployed to attack coronavirus in these individual spread scenarios. For example, the team argues that lamps could be deployed inside ventilation systems, with no direct optical path to occupants in the building, and run continuously, to disinfect ambient air. In other settings such as public restrooms, high-intensity UV-C light could be applied during the periods in which the rooms are unoccupied. And frequently touched surfaces, such as elevator buttons, might be subjected to continuous, weak UV-C illumination for ongoing disinfectionas human interactions with these surfaces tend to be brief, and thus would involve only a very low dose of radiation.

The team acknowledges that putting such an approach into effect would require a massive new deployment of UV lighting, with a correspondingly huge required uptick in its production. Yet the cost, they argue, may not be excessive, given the scale of the problem humanity now confrontsnot just in human mortality, but in the economic devastation that antiviral lockdowns have created.

The team estimates, in fact, that disinfection with fluorescence lamps could be implemented at a cost of a few dollars per person with minimum changes in infrastructure. Thus, they argue, a global capital investment of a few billion [U.S.] dollars could protect on the order of 109 indoor workers worldwide. The authors add, however, that current manufacturers of UV-C sources may have difficulty coping with the expected rise in demand originated by the SARS-CoV-2, pandemic, as the global market for UV-C light barely reaches one billion dollars a year at present.

Another team, based at Columbia Universitys Irving Medical Center, USA, took a different view of how UV-C might be used to fight coronavirus in occupied indoor settings (Sci. Reports, doi: 10.1038/s41598-020-67211-2). The team focused in particular on the specific wavelengths of UV-C light that might be used against the virusstressing that not all UV-C light is necessarily the same in terms of its hazard to human health.

Conventional germicidal lamps operate at a wavelength of 254 nm, as that is one of the sweet spots for UV-C absorption by DNA or RNA molecules; the light thus scrambles and inactivates the pathogens genetic machinery. It can also penetrate into the skin and eyes, causing similar genetic and other damage to living human cells.

The Columbia team points out, however, that light in the far UV-C, between 207 and 222 nm, is also effective at killing microorganismsyet studies to date suggest that these wavelengths do not cause the human health issues associated with the 254-nm radiation of germicidal lamps. The reason, according to the team, is that light in the far UV-C penetrates less than a few micrometers into biological materials. Thats too short a distance to pierce the nonliving protective layers of the skin and eye into the living cells beneath. But its more than sufficient to bore into tiny bacteria and viruses.

These considerations, the Columbia team argues, suggest that far-UV-C light should have about the same anti-microbial properties as conventional germicidal UV light, but without producing the corresponding health effects. Thus, they conclude, continuous, low-dose application of light in the wavelength area of 222 nm might be used in occupied public areas to stem the spread of SARS-CoV-2, without posing other hazards to the occupants themselves.

To test the idea out, the team used a misting device to aerosolize two common coronaviruses that were structurally similar to SARS-CoV-2, and then flowed the aerosols through the air in front of a 222-nm UV-C lamp. The researchers found that, at very low doses, the far UV-C light killed more than 99.9% of the viral load. The team is now at work on tests using the actual SARS-CoV-2 pathogenand says that preliminary data suggest that the far-UV-C light effectively kills that virus, too.

Putting these results together with the safety data, the team leader, David J. Brenner, asserted in a press release accompanying the work that far-UV-C at very low doses could be used in combination with other measures, like wearing face masks and washing hands, to limit the transmission of SARS-CoV-2 and other viruses.

See the rest here:
COVID-19: Putting UV-C to Work - Optics & Photonics News

Skin Stem Cells Comments Off on COVID-19: Putting UV-C to Work – Optics & Photonics News | June 26th, 2020

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe areVericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc.A large number of players are anticipated to enter the global market throughout the forecast period.

See the rest here:
Regenerative Medicine Market Analysis Growth Demand, Key Players, Share Size, and Forecast To 2025 - 3rd Watch News

Cardiac Stem Cells Comments Off on Regenerative Medicine Market Analysis Growth Demand, Key Players, Share Size, and Forecast To 2025 – 3rd Watch News | June 26th, 2020

Eustasis Psychiatric & Addiction Health

417-322-6622| 3600 S. National Ave., Springfield

Eustasis Psychiatric & Addiction Health is pleased to announce construction of their brand new site in the heart of Medical Mile, opening in July! There is expanded access to medication management, psychotherapy, testing and advanced treatment options.

Dr. Alok Jain and his wife Breanna Jain started the clinic in 2018 with the mission of providing the highest quality psychiatric care to all patients. Since then they have put together an amazing team of board-certified providers and support staff who have tirelessly served the Springfield community.

We wanted to build something really vital for our patients. A place that everyone could come, regardless of age or diagnosis, says Dr. Jain.

Dr. Alok Jain has been honored as a 417 Top Doctor every year since 2007 and is 2020's top psychiatrist. He is a board-certified psychiatrist, member of the American Psychiatric Association and has an extensive background in consultation-liaison psychiatry and psychopharmacology.

Eustasiss immediate-access site has provided patients with an unprecedented way to receive psychiatric care without delay. Their walk-in and be seen model is changing the face of psychiatry. The new location has eight providers and room for growth! They are providing the most state of the art modalities, including ADHD testing and esketamine.

It is super exciting, says Breanna Jain, CEO, PMHNP-BC. We have patients who come in all hours of the day, pediatric or adult, all payor sources. They will ask, You mean I can really be seen right now? We can proudly tell them of course! This is just the way we believe mental health should be done.

Both Dr. Jain and Breanna know that people need options in this community. Patients struggles are numerous, ranging from addiction, bipolar, ADHD, trauma, anxiety and more. The Jains like to think of Eustasis as a one-stop-shop.

There shouldnt be high levels of bureaucracy. This is what overwhelms patients. Barriers have no place when it comes to mental health, the Jains explain.

Eustasis is committed to helping patients find the optimal balance of emotions during these difficult times. They have expanded their hours and have both in person and telemedicine options available. They are always accepting new patients!

See original here:
Medical Professionals in the Ozarks - 417mag

Cardiac Stem Cells Comments Off on Medical Professionals in the Ozarks – 417mag | June 26th, 2020

One day before Sila Jio Boonklomjit was set to donate desperately needed stem cells to save his sisters life, doctors made an alarming discovery: Hed contracted COVID-19.

The 5-year-old COVID-19 patient is now being credited with saving his big sisters life by going through with an experimental procedure to cure her of a genetic blood disorder without passing along the coronavirus.

Saying it was the first known case of such a procedure, Ramathibodi Hospital claimed victory yesterday after successfully transplanting bone marrow from Jio to his sister, Jintanakan Jean Boonklomjit, who was born with thalassemia and was in a severe condition.

Its as if my daughter is reborn and gets a new life, said the childrens father, Suchai Boonklomjit.

Thalassemia is a hereditary disorder that limits the bloods ability to carry oxygen and affects an estimated 1% of all Thais. Rather than being treated by ongoing blood transfusions, recent breakthroughs have shown it can be cured through gene therapy.

The procedure began in April but wasnt completed until yesterday by Suradej Hongeng of the hospitals pediatrics department.

Posted by onTuesday, June 23, 2020

According to Suradej, it was a long and uncertain road to this happy outcome. It had been difficult to find a donor compatible with Jean, leading them to settle on Jio as her best hope. After they were confirmed to be a genetic match in 2018, they prepared for the transplantation procedure.

Other difficulties followed, in part due to the young age of both patients. Moreover, Jeans immune system was compromised by chemotherapy while Jio had to be placed in quarantine on the eve of the procedure. Doctors believe he was likely infected by his mother, Sasiwimol Boonklomjit.

The case is believed to be the first successful stem cell transplant from a donor with active COVID-19. Both Jio and his mother have since recovered from the virus.

Read more of Coconuts Bangkoks content here.

This article, 5-year-old Thai boy with COVID-19 saves sisters life with his stem cells, originally appeared on Coconuts, Asia's leading alternative media company. Want more Coconuts? Sign up for our newsletters!

Read more:
5-year-old Thai boy with COVID-19 saves sisters life with his stem cells - Yahoo Singapore News

Bone Marrow Stem Cells Comments Off on 5-year-old Thai boy with COVID-19 saves sisters life with his stem cells – Yahoo Singapore News | June 25th, 2020